within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL10_FormoterolAndTiotropiumBromide;
model FormoterolAndTiotropiumBromide 
   extends Pharmacolibrary.Drugs.ATC.R.R03AL10;

  annotation(Documentation(
    info ="<html><body><p>Formoterol and tiotropium bromide is a fixed-dose combination inhaler containing a long-acting beta2-adrenergic agonist (formoterol) and a long-acting muscarinic antagonist (tiotropium). It is used as a maintenance treatment of chronic obstructive pulmonary disease (COPD) to improve airflow and reduce exacerbations. This combination is approved and used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults with COPD following inhaled administration of fixed-dose combination formoterol and tiotropium bromide. No dedicated population PK model publication for the fixed combination was found; approximate parameters referenced are based on known single-agent PKs and inhaled route estimates.</p><h4>References</h4><ol><li><p>Tashkin, DP, et al., &amp; Denis-Mize, K (2008). Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. <i>Respiratory medicine</i> 102(4) 479–487. DOI:<a href=&quot;https://doi.org/10.1016/j.rmed.2007.12.019&quot;>10.1016/j.rmed.2007.12.019</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18258423/&quot;>https://pubmed.ncbi.nlm.nih.gov/18258423</a></p></li><li><p>Williamson, PA, et al., &amp; Lipworth, BJ (2010). Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD. <i>Chest</i> 138(3) 595–604. DOI:<a href=&quot;https://doi.org/10.1378/chest.10-0247&quot;>10.1378/chest.10-0247</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20418370/&quot;>https://pubmed.ncbi.nlm.nih.gov/20418370</a></p></li><li><p>Cazzola, M, et al., &amp; Centanni, S (2004). The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. <i>Pulmonary pharmacology &amp; therapeutics</i> 17(1) 35–39. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2003.09.001&quot;>10.1016/j.pupt.2003.09.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14643169/&quot;>https://pubmed.ncbi.nlm.nih.gov/14643169</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end FormoterolAndTiotropiumBromide;
